AGC Biologics and Repair Biotechnologies have announced a collaboration aimed at advancing an mRNA-based therapeutic designed to reduce and stabilize atherosclerotic plaque. The approach targets a major unmet medical need, rupture-prone plaque in large arteries remains the predominant cause of myocardial infarction and stroke and is implicated in more than a quarter of global mortality.
For clients like Repair Biotechnologies, we can be the most cost-effective, reliable, cGMP provider that can take life-saving mRNA treatments through the journey from preclinical to commercial stages. As the friendly CDMO expert, this is emblematic of our no-frills, expert approach is economical while never compromising good manufacturing and quality. Our approach ensures developers can radically transform quality of life around the world without breaking the bank.
Alberto Santagostino, CEO, AGC Biologics
Repair Biotechnologies is developing an mRNA modality intended to degrade intracellular excess free cholesterol, a pathological feature associated with plaque progression and reduced vascular stability. According to the company, the goal is to reverse aspects of cardiovascular disease previously considered refractory to therapeutic intervention. The platform builds on post-pandemic advances in nucleic-acid therapeutics and reflects a broader trend in applying mRNA technologies beyond infectious-disease vaccines to chronic and age-associated conditions.
Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress. We chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable path to the GMP drug product needed for our clinical trials. We are pleased to work with AGC Biologics to advance our mission to help people enjoy longer, healthier lives.
Reason, CEO and co-founder, Repair Biotechnologies
The partnership centers on AGC Biologics’ integrated manufacturing capabilities, which span plasmid DNA production through final mRNA drug-product formulation in lipid nanoparticles. Consolidation of these steps into a single facility is expected to reduce manufacturing complexity and shorten the transition from preclinical development to clinical evaluation. AGC Biologics’ Heidelberg site employs single-use systems and operates under EMA and FDA-aligned GMP standards.